Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lilly Will Tap Ambrx’s ReCODE Technology To Develop Metabolic, CNS Candidates

This article was originally published in The Pink Sheet Daily

Executive Summary

Partnership aims to yield first-in-class or best-in-class therapeutic antibodies and improved variants of native proteins, Ambrx tells “The Pink Sheet” DAILY.

You may also be interested in...



Ambrx Lands New Merck Serono Deal, This Time In Multiple Sclerosis

After boosting staff by 50 percent, Ambrx has cash runway through late 2011 or 2012, CEO says.

Ambrx Lands New Merck Serono Deal, This Time In Multiple Sclerosis

After boosting staff by 50 percent, Ambrx has cash runway through late 2011 or 2012, CEO says.

Lilly Inks Deal With BioMS For Phase III Multiple Sclerosis Compound

Collaboration valued at $497 million plus royalties aims to develop, commercialize synthetic peptide MBP8298, Lilly tells “The Pink Sheet” DAILY.

Topics

UsernamePublicRestriction

Register

PS065528

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel